
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
AbTherx and GPCR Therapeutics Partner to Develop Antibody Therapies for GPCRs
Details : The collaboration aims to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Wield Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
AbTherx and Wield Therapeutics Partner to Advance New Antibody Therapies
Details : The partnership will leverage AbTherx's innovative Atlas™ Full Human Diversity Transgenic Mouse technology to deliver antibodies against a target selected by Wield.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Wield Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Vaccinex
Deal Size : Undisclosed
Deal Type : Collaboration
AbTherx, SCT, and Vaccinex Join Forces on Hard-to-Target Antibody Drugs
Details : AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb® Technology into their respective workflows for complex drug targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Vaccinex
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Spice Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration
AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration
Details : The partnership will leverage AbTherx's suite of innovative Atlas Mouse technologies to deliver antibodies against targets selected by Spice Bio.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Spice Biotechnologies
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Rondo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
AbTherx and Rondo Therapeutics Announce Multi-Program Antibody Discovery Collaboration
Details : Under the terms of the licensing agreement, Rondo has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 23, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Rondo Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
